Spatially Explicit Integrated Risk Assessment of Present Soil Concentrations of Cadmium, Lead, Copper and Zinc in The Netherlands

Historic and current agricultural and industrial activities have resulted in accumulation of Cd, Cu, Pb and Zn in soil. To estimate potential risks for ecosystems, agriculture and water quality, an integrated risk assessment was performed for The Netherlands. Risks of metal contamination were assessed on a national scale by comparing present soil concentrations of Cd, Pb, Cu and Zn with critical concentrations of those metals in view of agricultural impacts, ecological impacts and impacts on the quality of groundwater and surface waters. Results show that present soil metal concentrations cause few risks for agriculture or ecosystems; for less than 2% of the surface area present metal levels exceed critical limits. Critical limits for groundwater are only significantly exceeded for Pb (17% of the area), but critical limits for surface water are exceeded throughout the country for Cu and Zn. Taking critical limits used in The Netherlands, the area where exceedances take place is nearly negligible for Cd and low for Pb (less than 3%), but much larger (between 40% and 50%) for both Cu and Zn. Results from this study suggest that accumulation of heavy metals in Dutch soils at present primarily affects the quality of surface waters. This stresses the need for harmonization of soil and water policy. Measures to reduce the load in surface waters to meet target levels, under conditions like those prevailing in The Netherlands, are bound to have an impact on land management.     

Cancer regression in patients after transfer of genetically engineered lymphocytes

Through the adoptive transfer of lymphocytes after host immunodepletion, it is possible to mediate objective cancer regression in human patients with metastatic melanoma. However, the generation of tumor-specific T cells in this mode of immunotherapy is often limiting. Here we report the ability to specifically confer tumor recognition by autologous lymphocytes from peripheral blood by using a retrovirus that encodes a T cell receptor. Adoptive transfer of these transduced cells in 15 patients resulted in durable engraftment at levels exceeding 10% of peripheral blood lymphocytes for at least 2 months after the infusion. We observed high sustained levels of circulating, engineered cells at 1 year after infusion in two patients who both demonstrated objective regression of metastatic melanoma lesions. This study suggests the therapeutic potential of genetically engineered cells for the biologic therapy of cancer.